A Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis

• Conditions: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10.000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride thereby reducing the formation of mucus plugs and improving clearance.; MedDRA version: 9.1Level: PTClassification code 10011763Term: Cystic fibrosis lung

• Registration Number: EUCTR2006-006693-24-HU
• Lead Sponsor: AOP Orphan Pharmaceuticals AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06-18
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1.Male or female subjects of 12 years of age or older
2.Body mass index equal or above -2 SDS (Standard Deviation Score-According to CDC standards) for 12-19 year old patients and greater/equal 18.5 kg/m2 for adults 20 years old and older
3.Have a confirmed diagnosis of cystic fibrosis:
positive sweat chloride value greater/equal 60 mEq/l by quantitative pilocarpine iontophoresis (on at least 2 occasions, if no genotype was determined) and/or
genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype
Measurement of nasal potential difference could be considered as an additional diagnostic tool, if results of sweat chloride test and genotype test are not unambiguous. Nasal potential difference test can not replace any of the above tests and should not be interpreted in isolation.
4.Have Screening FEV1 between 50% and 85% of predicted.
5.Have oxygen saturation level measured by pulse oximetry (SpO2) greater 90 % on room air

Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Show bronchial hyperresponsiveness as known from previous visits e.g. the subject needs additional puffs of salbutamol (or other beta-2-agonists) more than twice daily. This also applies to subjects who have shown bronchoconstriction to previously administered inhalation therapies or a decrease of FEV1 greater/equal 20% during or after administration of placebo at the screening visit
2.Have shown any evidence for unstable lung function, e.g. have had more than 15% FEV1 variation (difference between highest and lowest measured value in % of highest value measured) in the last 3 months before treatment starts (i.e. visit 2)
3.Have a pulmonary disease such as pneumonia, tuberculosis, or lung cancer
4.Have had an acute upper respiratory tract infection within the last 2 weeks
5.Have had an acute lower respiratory tract infection (requiring antibiotics or hospitalization) within the last 4 weeks
6.Have had an pulmonary exacerbation within the last 4 weeks
7.Have had any changes from routine maintenance therapy within the last 4 weeks
8.Have any scheduled changes to inhaled antibiotics regimen during the course of the study
9.Receive or are planned to receive any treatment via on-off” regimen (e.g. Tobramycin – TOBI®)
10.Have received the last dose of any on-off” treatment within the last 6 weeks
11.Have any clinically significant liver, renal, cardiac (as defined by QTc >450 msec (or 0.450 seconds) for males or QTc> 470 msec (or 0.470 seconds) for females), neurological, or hematological disease
12.Have allergic bronchopulmonary aspergillosis or colonization with Burkholderia cepacia
13.Have poorly controlled diabetes mellitus
14.Have smoked more than 3 cigarettes per day within the last 12 months.
15.Have a history of alcohol (> 40g/day) or drug abuse
16.Have participated in an investigational drug study (including Moli1901) within the last 8 weeks
17.Are women of child bearing potential and refuse to use effective contraception or are pregnant or lactating
18.Are unwilling to perform appropriate safe contraception for at least 6 months after investigational product administration

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified